Any process that activates or increases the frequency, rate or extent of the addition of one or more phosphate groups to a histone protein.

Any process that activates or increases the frequency, rate or extent of histone H2B ubiquitination.

Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.

Any process that modulates the frequency, rate or extent of DNA repair.

The synthesis of RNA from a DNA template by RNA polymerase II (RNAP II), originating at an RNA polymerase II promoter. Includes transcription of messenger RNA (mRNA) and certain small nuclear RNAs (snRNAs).

Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.

The extension of an RNA molecule after transcription initiation and promoter clearance at an RNA polymerase II promoter by the addition of ribonucleotides catalyzed by RNA polymerase II.

The process of introducing a phosphate group on to a protein.

The multiplication or reproduction of cells, resulting in the expansion of a cell population.

Any process that modulates the frequency, rate or extent of the covalent alteration of a histone.

The process in which a DNA replication fork that has stalled is restored to a functional state and replication is restarted. The stalling may be due to DNA damage, DNA secondary structure, bound proteins, dNTP shortage, or other causes.

The synthesis of small nuclear RNA (snRNA) from a DNA template by RNA Polymerase II (Pol II), originating at a Pol II promoter.

Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.

Any process that activates or increases the frequency, rate or extent of viral transcription.

Any process that modulates the frequency, rate or extent of muscle cell differentiation.

Any process that decreases the rate, frequency, or extent of cell cycle arrest, the process in which the cell cycle is halted during one of the normal phases.

Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokine stimulus.

Any process that stops, prevents or reduces the frequency, rate or extent of mRNA polyadenylation.

Any process that activates or increases the frequency, rate or extent of mRNA 3'-UTR binding.

Any process that modulates the frequency, rate or extent of DNA repair.

The process of introducing a phosphate group on to a protein.

Any process that increases the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division.

Any process that increases the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division.

Any process that modulates the frequency, rate or extent of the covalent alteration of a histone.

The process in which a DNA replication fork that has stalled is restored to a functional state and replication is restarted. The stalling may be due to DNA damage, DNA secondary structure, bound proteins, dNTP shortage, or other causes.

Any process that activates or increases the frequency, rate or extent of the addition of one or more phosphate groups to a histone protein.

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease.

Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.

Any process that modulates the frequency, rate or extent of muscle cell differentiation.

Any process that decreases the rate, frequency, or extent of cell cycle arrest, the process in which the cell cycle is halted during one of the normal phases.

Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokine stimulus.

Any process that stops, prevents or reduces the frequency, rate or extent of mRNA polyadenylation.

Any process that activates or increases the frequency, rate or extent of mRNA 3'-UTR binding.

Any process that activates or increases the frequency, rate or extent of histone H2B ubiquitination.

Any host process that results in the promotion of antiviral immune response mechanisms, thereby limiting viral replication.

The cellular synthesis of RNA on a template of DNA.

The extension of an RNA molecule after transcription initiation and promoter clearance at an RNA polymerase II promoter by the addition of ribonucleotides catalyzed by RNA polymerase II.

The process of introducing a phosphate group on to a protein.

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heat stimulus, a temperature stimulus above the optimal temperature for that organism.

Any process that modulates the frequency, rate or extent of cardiac muscle cell proliferation.

Any process that modulates the frequency, rate or extent of cardiac muscle cell proliferation.

The regrowth of cardiac muscle tissue to repair injured or damaged muscle fibers in the postnatal stage.

The regrowth of cardiac muscle tissue to repair injured or damaged muscle fibers in the postnatal stage.

The immediate defensive reaction by vertebrate tissue to injury caused by chemical or physical agents.

The process whose specific outcome is the progression of the nematode larva over time, from its formation to the mature structure. Nematode larval development begins with the newly hatched first-stage larva (L1) and ends with the end of the last larval stage (for example the fourth larval stage (L4) in C. elegans). Each stage of nematode larval development is characterized by proliferation of specific cell lineages and an increase in body size without alteration of the basic body plan. Nematode larval stages are separated by molts in which each stage-specific exoskeleton, or cuticle, is shed and replaced anew.

The process whose specific outcome is the progression of an immature germ cell over time, from its formation to the mature structure (gamete). A germ cell is any reproductive cell in a multicellular organism.

The process whose specific outcome is the progression of an embryo over time, from zygote formation until the end of the embryonic life stage. The end of the embryonic life stage is organism-specific and may be somewhat arbitrary; for mammals it is usually considered to be birth, for insects the hatching of the first instar larva from the eggshell.

Any process that modulates the frequency, rate or extent of phosphorylation of RNA polymerase II C-terminal domain.

Any process that modulates the frequency, rate or extent of histone H3-K36 trimethylation.

That part of the nuclear content other than the chromosomes or the nucleolus.

A ribonucleoprotein granule located in the cytoplasm.

A transcription elongation factor complex that facilitates the transition from abortive to productive elongation by phosphorylating the CTD domain of the large subunit of DNA-directed RNA polymerase II, holoenzyme. Contains a cyclin and a cyclin-dependent protein kinase catalytic subunit.

That part of the nuclear content other than the chromosomes or the nucleolus.

Any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation.

Any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation.

A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.

A class of nuclear body; they react against SP100 auto-antibodies (PML, promyelocytic leukemia); cells typically contain 10-30 PML bodies per nucleus; alterations in the localization of PML bodies occurs after viral infection.

A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

Any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation.

A transcription elongation factor complex that facilitates the transition from abortive to productive elongation by phosphorylating the CTD domain of the large subunit of DNA-directed RNA polymerase II, holoenzyme. Contains a cyclin and a cyclin-dependent protein kinase catalytic subunit.

A transcription elongation factor complex that facilitates the transition from abortive to productive elongation by phosphorylating the CTD domain of the large subunit of DNA-directed RNA polymerase II, holoenzyme. Contains a cyclin and a cyclin-dependent protein kinase catalytic subunit.

A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

That part of the nuclear content other than the chromosomes or the nucleolus.

Any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation.

A transcription elongation factor complex that facilitates the transition from abortive to productive elongation by phosphorylating the CTD domain of the large subunit of DNA-directed RNA polymerase II, holoenzyme. Contains a cyclin and a cyclin-dependent protein kinase catalytic subunit.

A class of nuclear body; they react against SP100 auto-antibodies (PML, promyelocytic leukemia); cells typically contain 10-30 PML bodies per nucleus; alterations in the localization of PML bodies occurs after viral infection.

A ribonucleoprotein granule located in the cytoplasm.

A type of chromosome in a polyploid cell, formed when multiple copies of homologous chromosomes are aligned side by side to give a giant chromosome in which distinct chromosome bands are readily visible.

A swelling at a site along the length of a polytene chromosome, thought to be the site of active transcription.

A heterodimeric protein complex that acts as an RNA polymerase II elongation factor; the complex is conserved from yeast to humans, and is present in S. pombe, but absent from S. cerevisiae.

A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information.